ALTO NEUROSCIENCE

Alto Neuroscience, founded in 2019 by Dr. Amit Etkin, is a clinical-stage biopharmaceutical company headquartered in Mountain View, California. The company is pioneering precision psychiatry by developing personalised treatments for neuropsychiatric conditions, utilising an AI-enabled biomarker platform to match patients with the most effective therapies.

Building upon over 15 years of neuroscience research, Alto's approach integrates comprehensive data on brain activity and behaviour to identify patients likely to respond to their novel drug candidates. This strategy aims to move beyond the traditional trial-and-error method in psychiatric care, offering targeted solutions for conditions such as major depressive disorder, bipolar depression, and schizophrenia.

Alto's leadership team comprises experts in psychiatric drug development, neuroscience, and clinical psychiatry, all dedicated to advancing personalised and data-driven treatments. By focusing on the underlying neurobiology of mental health disorders, Alto Neuroscience strives to provide patients with faster and more effective therapeutic options.

‍